OSR Health Inc（OSRH）资讯与事件OSRHOSR Health Inc

OSRH CEO Confirms Subsidiaries' Technologies Received Inquiries

CEO Peter Hwang said, in part, "Today marks five business days before August 18, the practical deadline by which the Nasdaq is expected to communicate its determination regarding OSRH's continued listing if our stock price has not regained the minimum bid price requirement of $1.00 per share as of the market close. As CEO of OSRH, I want to assure our shareholders that I remain deeply confident in the fundamental value we are building across our Company and its subsidiaries. I also want to share an important development with the market. Without disclosing confidential information or identifying the parties involved at this stage, I can confirm that two of our subsidiaries have received inbound inquiries regarding potential out-licensing opportunities for their technologies and products. Of the two, one is at the preliminary term sheet negotiation phase while the other is in early stage. I believe both of these represent meaningful validation of the value of the intellectual property and businesses that we have worked so hard to develop. I fully understand the significance of making this statement as the CEO of a Nasdaq-listed public company. I am making it because I believe our shareholders deserve to know that meaningful business developments are taking place behind the scenes. Time will tell, and I believe that time will tell sooner rather than later... There is still uncertainty ahead, and I will not make promises about outcomes that are not yet within our control. But I can make this promise: we will continue to fight for the Company, for the businesses we have built, and for the interests of our shareholders. I have invested alongside you, I remain invested alongside you, and I remain committed to seeing the value of what we have built recognized by the market."

OSR Health Subsidiary Vaximm Completes Analysis of VXM01 Clinical Studies

OSR Health announced that its subsidiary Vaximm has completed the analysis of results from two clinical studies evaluating VXM01, an oral DNA vaccine targeting the vascular endothelial growth factor receptor 2, in patients with recurrent glioblastoma. Prof. Wolfgang Wick, M.D., Chairman of the Neurology Clinic of Heidelberg University and the principal investigator of these trials, commented that "these results are indeed encouraging with regard to moving this concept further in the clinic." The Company intends to submit these findings to a peer-reviewed scientific journal and is expected to announce further top-line results soon, including the direction of future clinical development of VXM01 and its platform.

OSRH CEO Emphasizes Value Enhancement for Biotech Company

In a shareholder letter, CEO Peter Hwang said, in part, "Over the past year, we have continued to strengthen our position as a biomedical holding company with a growing portfolio of innovative businesses spanning oncology, regenerative medicine, medical devices, and digital health. We are seeing increasing external validation of the technologies and platforms being developed by our subsidiaries. Vaximm recently executed a definitive licensing agreement for the VXM01 immunotherapy platform, one of the most significant transactions in the Company's history. At Woori IO, development activities and strategic engagements involving global industry participants, including Samsung, continue to advance our noninvasive glucose monitoring platform. Across our portfolio, we are focused on transforming scientific innovation into commercial opportunities and long-term shareholder value. As a holding company, our responsibility is to continually evaluate how best to unlock the value of our underlying businesses for the benefit of shareholders. Public markets have repeatedly demonstrated that significant value can be created through thoughtful capital allocation, strategic partnerships, subsidiary monetizations, spin-offs, and other corporate actions that allow investors to participate more directly in the success of underlying assets. While we are not announcing any specific transaction at this time, I can assure shareholders that we are evaluating a full range of tools available to publicly listed Hub-and-Spoke biotech companies and are committed to pursuing opportunities that we believe will benefit our investors. We continue to work closely with Nasdaq, our advisors, and industry experts regarding our minimum bid price compliance process. Maintaining a Nasdaq listing remains an important objective, and we are evaluating pathways to achieve compliance while preserving and enhancing long-term shareholder value...The next chapter of OSRH will not be defined by a compliance deadline or short-term considerations such as the next quarter or month, but by its ability to translate scientific innovation into enduring shareholder value. We remain confident in our portfolio, our partners, and the opportunities before us, and we appreciate the continued trust and support of our shareholders as we execute our strategy."